Wong Newton A C S, Amary Fernanda, Butler Rachel, Byers Richard, Gonzalez David, Haynes Harry R, Ilyas Mohammad, Salto-Tellez Manuel, Taniere Philippe
Department of Cellular Pathology, Southmead Hospital, Bristol, UK.
Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital, Stanmore, UK.
J Clin Pathol. 2018 May;71(5):388-394. doi: 10.1136/jclinpath-2017-204943. Epub 2018 Feb 8.
The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. The decision to treat with the biologic trastuzumab is completely dependent on HER2 testing of tumour tissue. In 2017, the College of American Pathologists, American Society for Clinical Pathology and the American Society of Clinical Oncology jointly published guidelines for HER2 testing and clinical decision making in gastro-oesophageal adenocarcinoma. The Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee has issued the following document as a commentary of these guidelines and, in parallel, to provide guidance on HER2 testing in National Health Service pathology departments within the UK. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such HER2 testing.
针对人表皮生长因子受体2（HER2）蛋白的生物制剂的使用是用于对抗晚期胃癌或胃食管交界腺癌的武器库中的最新成员。使用生物制剂曲妥珠单抗进行治疗的决定完全取决于肿瘤组织的HER2检测。2017年，美国病理学家学会、美国临床病理学会和美国临床肿瘤学会联合发布了胃食管腺癌HER2检测和临床决策指南。临床病理学家协会分子病理学和诊断委员会发布了以下文件，作为对这些指南的评论，并同时为英国国家医疗服务体系病理科的HER2检测提供指导。本指南涵盖了与病例选择、分析前方面、此类HER2检测的分析和解释相关的问题。
